Aneel Bhangu1, S Mohammed Ali, Gina Brown, R John Nicholls, Paris Tekkis. 1. *Department of Colorectal Surgery, the Royal Marsden Hospital, London †Division of Surgery, Chelsea and Westminster Campus, Imperial College London, London ‡Department of Radiology, the Royal Marsden Hospital, London; and §Division of Surgery, Imperial College, St Mary's Hospital, London.
Abstract
OBJECTIVE: The outcome of pelvic exenteration was compared in patients with locally advanced primary (LAP) cancer and recurrent rectal cancer (RRC). BACKGROUND: There are few reports comparing the results of pelvic exenteration for primary advanced rectal cancer and RRC. METHODS: Consecutive patients undergoing pelvic exenteration between 2006 and 2011 were identified from a prospectively maintained database. The main endpoints were 3-year disease-free survival (DFS) and local recurrence-free survival (LRFS). RESULTS: Of 100 exenterative operations, 55 were for LAP cancer and 45 for RRC. Exenteration of 1 pelvic compartment was required in 30 cases, 2 compartments in 49 cases, and 3 of 4 compartments in 21 cases. R0, R1, and R2 resections were achieved in 78, 15, and 7 cases, respectively. R0 rates were significantly higher in LAP cancer than in RRC (91% vs 62%, P = 0.001). Three-year DFS for R0, R1, and R2 resections was 67%, 49%, and 0%, respectively (P < 0.001). For R0 resections only, DFS in LAP cancer was 76% and 57% in RRC (P = 0.212). On multivariate analysis, a positive resection margin (hazard ratio, 4.04; P < 0.001) and positive lymph node staging (hazard ratio, 2.43; P = 0.022) were significant predictors of reduced DFS. Three-year LRFS for R0 resection was 86% for LAP cancer and 84% for RRC (P = 0.817). On multivariate analysis, only a positive resection margin was a significant predictor of reduced LRFS (hazard ratio, 5.48; P = 0.002). CONCLUSIONS: Resection margin status is more important than primary or recurrent cancer in predicting long-term outcome.
OBJECTIVE: The outcome of pelvic exenteration was compared in patients with locally advanced primary (LAP) cancer and recurrent rectal cancer (RRC). BACKGROUND: There are few reports comparing the results of pelvic exenteration for primary advanced rectal cancer and RRC. METHODS: Consecutive patients undergoing pelvic exenteration between 2006 and 2011 were identified from a prospectively maintained database. The main endpoints were 3-year disease-free survival (DFS) and local recurrence-free survival (LRFS). RESULTS: Of 100 exenterative operations, 55 were for LAP cancer and 45 for RRC. Exenteration of 1 pelvic compartment was required in 30 cases, 2 compartments in 49 cases, and 3 of 4 compartments in 21 cases. R0, R1, and R2 resections were achieved in 78, 15, and 7 cases, respectively. R0 rates were significantly higher in LAP cancer than in RRC (91% vs 62%, P = 0.001). Three-year DFS for R0, R1, and R2 resections was 67%, 49%, and 0%, respectively (P < 0.001). For R0 resections only, DFS in LAP cancer was 76% and 57% in RRC (P = 0.212). On multivariate analysis, a positive resection margin (hazard ratio, 4.04; P < 0.001) and positive lymph node staging (hazard ratio, 2.43; P = 0.022) were significant predictors of reduced DFS. Three-year LRFS for R0 resection was 86% for LAP cancer and 84% for RRC (P = 0.817). On multivariate analysis, only a positive resection margin was a significant predictor of reduced LRFS (hazard ratio, 5.48; P = 0.002). CONCLUSIONS: Resection margin status is more important than primary or recurrent cancer in predicting long-term outcome.
Authors: Peng Du; John P Burke; Wisam Khoury; Ian C Lavery; Ravi P Kiran; Feza H Remzi; David W Dietz Journal: Int J Colorectal Dis Date: 2016-02-10 Impact factor: 2.571
Authors: I Shaikh; W Aston; G Hellawell; D Ross; S Littler; D Burling; M Marshall; J M A Northover; A Antoniou; J T Jenkins Journal: Tech Coloproctol Date: 2014-11-08 Impact factor: 3.781
Authors: Oliver Peacock; Peadar S Waters; Joseph C Kong; Satish K Warrier; Chris Wakeman; Tim Eglinton; Declan G Murphy; Alexander G Heriot; Frank A Frizelle; Jacob J McCormick Journal: Tech Coloproctol Date: 2020-01-06 Impact factor: 3.781